Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 25,000 shares at $45.39 ($1.1M) on 2013-07-08, disclosed to the SEC on 2013-07-10.
Scheduled sale ($1.1M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |